---
workstream: WS:BIOCATALYST-RECOVERY-V2
session: sol/biocatalyst-recovery-v2-p0-production-closeout
model: codex
ended_because: complete
prs: [6090]
decisions:
  - DEC:BIOCATALYST-RECOVERY-V2-CORE-NOT-JV-OR-BCI
discoveries: []
mission: >
  Reconcile the canonical BioCatalyst Recovery V2 workstream after real entitled
  production proof #6090 satisfied the frozen recovery objective, close recovery
  without converting it into a parity/alpha catch-all, and return post-P0 product
  continuation to a separate Sol CEO adjudication.
state_before: >
  #6052 had merged after independent PASS and WS:BIOCATALYST-RECOVERY-V2 correctly
  named entitled production acceptance as the final P0 gate. Macro #6090 then landed
  the missing real production receipt, but the Agent OS workstream still said
  P0-C2-PROD-ACCEPT=todo and next_action=deploy/prove.
changed:
  - path: agentos/workstreams/WS-BIOCATALYST-RECOVERY-V2.md
    what: >
      Marks the recovery workstream done, records #6090 as the completed production
      acceptance wave, preserves the exact P0 proof boundaries, and makes post-P0
      continuation a separate Sol-ratified program rather than silently extending
      recovery.
  - path: agentos/handoffs/BIOCATALYST-RECOVERY-V2-2026-08-20-p0-production-closeout.md
    what: >
      Cold-stranger closeout with the production receipt, non-claims, durable
      no-rebuild boundaries and exact continuation authority.
verified:
  - claim: BioCatalyst P0 hydration is proven on the real entitled served path.
    command: Read merged Macro PR #6090 and its production acceptance artifact.
    result: >
      #6090 is merged as e4c2e3b9f83585d7de812ccc55336c6e7fd9d897. The receipt
      binds the test to macro-api MainPID 2529475 serving #6052 commit 427d676de1a,
      records health 200/fresh, Trial Screen 200 with four real NCT rows, facets 200,
      lawful empty milestones and prospective state, Change Tape 200, covered dossier
      and peer-set 200, unsigned 401, invalid-sort 400, no 524 and no 5xx.
  - claim: The bounded repair is performant enough for the accepted P0 serving job.
    command: Read route timing matrix in P0_C2R2_PRODUCTION_ACCEPTANCE_2026-08-20.md.
    result: >
      Isolated entitled product routes completed roughly 4.5-7.9 seconds; no request
      approached the ~30 second edge ceiling. The receipt explicitly says a further
      process-lifetime ContractRegistry optimization is not required to call P0 green.
  - claim: P0 recovery completion is not product parity.
    command: Read #6090 conclusion and explicit non-claims.
    result: >
      The receipt says BIOCATALYST P0 — PROVEN_LIVE while explicitly refusing a
      BioPharmCatalyst-parity claim; the live workbench remains the current four-NCT
      ClinicalTrials.gov cohort.
  - claim: Source/soak, BPC JV and draft BCI remain separate authority domains.
    command: Read #6090 explicit non-claims and the existing workstream landmines.
    result: >
      #6090 did not alter source soak, JV runtime registration or draft BCI authority;
      this closeout preserves those boundaries.
unverified:
  - claim: This closeout branch passes final exact-head Agent OS/schema/hosted CI.
    what_would_verify: >
      Hosted CI/fences on the final records-only PR head plus a current-main semantic
      review before merge.
unresolved:
  - "Which post-P0 product/intelligence program should be commissioned next, if any."
  - "Whether the next highest-value BioCatalyst program is parity/workflow breadth, broader clinical/regulatory truth, alpha/asymmetry, Prophet integration, or a deliberate park."
next_actions:
  - "Merge this records-only closeout only after exact-head Agent OS/schema/CI is green."
  - "Keep Linear MAS-71 Done as the production-proof gate."
  - "Use Linear MAS-74 as the separate Sol post-P0 architecture adjudication; do not open implementation PRs from this recovery row."
  - "If Sol selects continuation, create a distinct workstream/capability ledger and commission one bounded vertical that reuses the proven BioCatalyst truth plane."
do_not_redo:
  - "Do not reopen P0 entitlement/hydration diagnosis after #6090 PROVEN_LIVE."
  - "Do not reopen ContractRegistry/bootstrap as a required P0 repair; production passed without it."
  - "Do not remap recovery or future parity to WS:BPC-JV-RECON."
  - "Do not treat draft BCI #5821 as merged product authority."
  - "Do not mutate source/soak law from a serving-recovery closeout."
  - "Do not call P0 production acceptance BioPharmCatalyst parity."
  - "Do not smuggle parity, alpha/asymmetry or Prophet work into this completed recovery workstream."
danger_areas:
  - "A completed recovery row can tempt downstream agents to call the whole BioCatalyst vision complete. Only the recovery objective is done; broader product parity remains explicitly unproven."
  - "Conversely, broader parity debt must not be used to keep this recovery row artificially active after its frozen production objective passed."
  - "Production proof used an existing entitled browser session without persisting credentials; preserve that evidence hygiene in future work."
---

# Return point

BioCatalyst Recovery V2 is complete as a recovery program. The decisive production receipt is
`research/biocatalyst_recovery_v2/P0_C2R2_PRODUCTION_ACCEPTANCE_2026-08-20.md` from merged #6090.
The next decision belongs to Sol under Linear MAS-74: either freeze a distinct post-P0 program
with one independently useful first vertical, or park further expansion. This handoff grants no
post-P0 implementation authority by itself.
